Marker Therapeutics, Inc. MRKR 深 滬
已收盤 02-06 16:00:00 美东时间
1.65
-0.010
-0.60%
華盛通- 最 高1.77
- 今 開1.66
- 成交量 23.34万股
- 最 低 1.64
- 昨 收 1.66
- 總市值 2751.07万
- 52周最高 4.07
- 市盈率 靜 --
- 換手率 1.40%
- 52周最低 0.8099
- 委 比 -89.62%
- 總股本 1667.31万
- 歷史最高 99.00
- 量 比 0.89
- 振 幅 7.83%
- 歷史最低 0.8099
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
Marker Therapeutics highlights advancements in Multi-Antigen Targeted T cell therapy for pancreatic cancer, which showed an 84.6% disease control rate in a Baylor study. Featured on *Good Morning America*, the therapy addresses a critical need in pancreatic cancer treatment. Marker plans to expand trials with enhanced antigen targeting and higher cell doses, supported by NIH and CPRIT funding.
01-26 12:00
Marker Therapeutics Highlights Nature Medicine Publication On Multi-Antigen T Cells In Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical studyStudy highlights correlation
01-05 20:17
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
A clinical study from Baylor College of Medicine demonstrates that Multi-Antigen Targeted T cells combined with front-line chemotherapy achieved an 84.6% disease control rate in pancreatic cancer patients, with a median overall survival of 14.1 months. The study, published in *Nature Medicine*, highlights the safety and potential of the therapy, correlating clinical benefits with T cell expansion and persistence. Marker Therapeutics, the company ...
01-05 12:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $10.
2025-12-08 22:44
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share
2025-11-14 06:31
Marker Therapeutics To Present Data From Phase 1 APOLLO Study Investigating MT-601 In Patients With Relapsed B Cell Lymphomas At ASH 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy dataMT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs)
2025-11-03 22:30
Marker Therapeutics Announces First Patient Treated In OTS Program, With Encouraging Preliminary Safety Data
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatmentOTS product was well tolerated - safety data
2025-10-06 19:33
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Phase 1 APOLLO study of MT-601 shows 66% objective response rate in NHL patients, with 50% achieving complete response. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or ICANS. The study will expand to investigate MT-601 at the maximum dose in DLBCL patients who relapsed after or are ineligible for CAR-T therapy. A live webcast discussing the results will be held today.
2025-08-26 11:00
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics' CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The session will focus on the Company's MAR T cell platform and clinical developments. Investors can access the webcast via Marker's Investor Relations website.
2025-07-30 12:00
